Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Kabunga, C. Handler, C. Das, S. Reddecliffe, C. Denton, C. Black, H. Penn, J. G. Coghlan, J. Davar (London, United Kingdom). Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival. Eur Respir J 2007; 30: Suppl. 51, 1592

Member's Comments

No comment yet.

Related content which might interest you: Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Vasodilator testing in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Screening for pulmonary arterial hypertension in systemic sclerosis Source: Eur Respir Rev 2009; 18: 162-169 Year: 2009 Gas transfer relates to pulmonary haemodynamics and survival in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Source: Eur Respir Rev 2011; 20: 270-276 Year: 2011 Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009